- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Results From the STEP Trial in China
A brief overview of the STEP trial and results from intensive blood-pressure control in elderly patients with hypertension.
EP: 1.An Overview of the FIGARO-DKD Trial Design
EP: 2.Results From FIGARO-DKD: Finerenone’s Impact on Type 2 Diabetes and CKD
EP: 3.An Overview of the FIDELITY Pooled Analysis Design
EP: 4.Results From the FIDELITY Pooled Analysis
EP: 5.Practical Implications of the FIDELITY Pooled Analysis
EP: 6.Results From FIGARO-DKD and FIDELITY: Finerenone + SGLT2 Inhibitors
EP: 7.Results From EMPEROR-Preserved: CV Outcomes in Patients With HFpEF
EP: 8.Results From the EMPEROR-Pooled Analysis
EP: 9.Unmet Needs in the Management of Heart Failure
EP: 10.Results From the STEP Trial in China
Transcript:
Rajiv Agarwal, MD, MS: One of the noteworthy trials to me was STEP, which was a large trial of more than 8000 patients in China between the ages of 60 and 80, randomized to 2 different blood pressure targets. The blood pressure target was 110 to 130 mm Hg and 130 to 150 mm Hg in a population of patients between 60 and 80 years old. They showed that cardiovascular outcomes are incredibly improved by treatment to a lower blood pressure target of 110 to 130 mm Hg. Well, it is a population of Chinese patients: 90% are Han Chinese, so it validates the results of the SPRINT trial to China.
Basically, what we found in the SPRINT trial in the United States is similarly what is being found in China. The goal here is that the broad application of blood pressure lowering to huge population segments, even when they are 60 years of age or older, can show benefit against cardiovascular disease down the road. That’s really noteworthy. In particular, I was impressed with hospitalization for heart failure, which was reduced by more than three-quarters by simply lowering blood pressure, and that’s really remarkable. People ought to pay attention to blood pressure, especially in people who are elderly.
Transcript edited for clarity.
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More
